Paper1707752
Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate.
Parker WB and 9 others. Cancer Res, 1991. Cited by 207 papers, by iCite.
Cite this record
ConductScience Library. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate. Papers, record 1707752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1707752
- Disease
- acute myeloid leukemia587 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate.
- PubMed
Connected records3
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Arabinonucleosides | Major topic |
| DNA | Major topic |
| Nucleic Acid Synthesis Inhibitors | Major topic |
| Ribonucleotide Reductases | Major topic |
| Adenine Nucleotides | |
| Adenosine Triphosphate | |
| Cell Division | |
| Clofarabine | |
| Cytidine Triphosphate | |
| Deoxycytidine | |
| Guanidine | |
| Guanidines | |
| Humans | |
| RNA | |
| Tumor Cells, Cultured |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| CA34200 | NCI NIH HHS | United States | P01CA034200 | PubMed and NIH |
Source NIH RePORTER
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00700011 | Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx) | Results |
Source ClinicalTrials.gov
Cited by78
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 207 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41890705 | Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial. | Blood Neoplasia | 2026 | https://conductscience.org/library/papers/41890705 | PubMed |
| 41881963 | The oncogenic control of nucleotide synthesis. | Oncogenesis | 2026 | https://conductscience.org/library/papers/41881963 | PubMed |
| 40615230 | Ribonucleotide reductase (RNR) inhibitors as target-based weapon for future cancer drug development. | Future Med Chem | 2025 | https://conductscience.org/library/papers/40615230 | PubMed |
| 40434346 | Clofarabine Enhances the Transduction Efficiency of Recombinant AAV2 in the Retina. | Invest Ophthalmol Vis Sci | 2025 | https://conductscience.org/library/papers/40434346 | PubMed |
| 40142132 | Synthesis of Adenine Nucleosides with a Reactive (β-Iodovinyl)sulfone or (β-Keto)sulfone Group at the C2 Position and Their Polymerase-Catalyzed Incorporation into DNA. | Molecules | 2025 | https://conductscience.org/library/papers/40142132 | PubMed |
| 39189649 | Connecting dots between nucleotide biosynthesis and DNA lesion repair/bypass in cancer. | Biosci Rep | 2024 | https://conductscience.org/library/papers/39189649 | PubMed |
| 38936939 | In Vivo Cytotoxic, Genotoxic and Radiosensitizing Effects of Clofarabine. | In Vivo | 2024 | https://conductscience.org/library/papers/38936939 | PubMed |
| 36151376 | Still no Rest for the Reductases: Ribonucleotide Reductase (RNR) Structure and Function: An Update. | Subcell Biochem | 2022 | https://conductscience.org/library/papers/36151376 | PubMed |
| 35740940 | Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present. | Biomolecules | 2022 | https://conductscience.org/library/papers/35740940 | PubMed |
| 34503994 | 5-Aza-4'-thio-2'-deoxycytidine, a New Orally Bioavailable Nontoxic "Best-in-Class": DNA Methyltransferase 1-Depleting Agent in Clinical Development. | J Pharmacol Exp Ther | 2021 | https://conductscience.org/library/papers/34503994 | PubMed |
| 31950591 | Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy. | EMBO Mol Med | 2020 | https://conductscience.org/library/papers/31950591 | PubMed |
| 31637757 | Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia. | Am J Hematol | 2020 | https://conductscience.org/library/papers/31637757 | PubMed |
| 30734609 | Structure-guided design of anti-cancer ribonucleotide reductase inhibitors. | J Enzyme Inhib Med Chem | 2019 | https://conductscience.org/library/papers/30734609 | PubMed |
| 29750747 | Haploidentical Donor Transplantation Using a Novel Clofarabine-containing Conditioning Regimen for Very High-risk Hematologic Malignant Neoplasms. | J Pediatr Hematol Oncol | 2018 | https://conductscience.org/library/papers/29750747 | PubMed |
| 29123979 | Inhibition of nonenzymatic depurination of nucleic acids by polycations. | FEBS Open Bio | 2017 | https://conductscience.org/library/papers/29123979 | PubMed |
| 28624910 | Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy? | J Cancer Res Clin Oncol | 2017 | https://conductscience.org/library/papers/28624910 | PubMed |
| 28394191 | The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells. | Leuk Lymphoma | 2017 | https://conductscience.org/library/papers/28394191 | PubMed |
| 28283480 | Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML. | Blood | 2017 | https://conductscience.org/library/papers/28283480 | PubMed |
| 27960273 | Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs. | Chem Rev | 2016 | https://conductscience.org/library/papers/27960273 | PubMed |
| 27879047 | 2-Substituted dATP Derivatives as Building Blocks for Polymerase-Catalyzed Synthesis of DNA Modified in the Minor Groove. | Angew Chem Int Ed Engl | 2016 | https://conductscience.org/library/papers/27879047 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| DCK | 1633 | PubTator's text mining | https://conductscience.org/library/genes/1633 | NCBI Gene |
| POLA1 | 5422 | PubTator's text mining | https://conductscience.org/library/genes/5422 | NCBI Gene |
| POLB | 5423 | PubTator's text mining | https://conductscience.org/library/genes/5423 | NCBI Gene |
| POLG | 5428 | PubTator's text mining | https://conductscience.org/library/genes/5428 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| CLOFARABINE | CHEMBL1750 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1750 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1707752
GET https://conductscience.org/api/papers/v1/1707752/cited_by?page=2